Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Drama Dendreon: Anticipated Provenge Launch Appears On Track

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech says it will launch prostate cancer vaccine the day after approval.

You may also be interested in...



PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?

FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.

PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?

FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.

Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size

FDA's Office of Oncology Drug Products is undergoing a reorganization aimed at making its structure more similar to the rest of the review offices in the Center for Drug Evaluation and Research

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel